MHCD:CA:TSX-Middlefield Healthcare Dividend ETF (CAD)

ETF | Others |

Last Closing

CAD 12.13

Change

+0.13 (+1.08)%

Market Cap

CAD 0.16B

Volume

2.01K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEQT:CA iShares Core Equity Portfolio

+0.18 (+0.53%)

CAD 6.78B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

+0.01 (+0.02%)

CAD 6.30B
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

+0.40 (+1.38%)

CAD 6.19B
PHYS-U:CA Sprott Physical Gold Trust

+0.16 (+0.69%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

+0.41 (+1.16%)

CAD 4.54B
HXT-U:CA Global X S&P/TSX 60 Index ETF

+0.84 (+1.90%)

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

+0.11 (+0.40%)

CAD 3.78B
ZMMK:CA BMO Money Market Fund ETF Seri..

+0.01 (+0.01%)

CAD 3.55B
PSLV-U:CA Sprott Physical Silver Trust

+0.09 (+0.78%)

CAD 3.29B
NSCB:CA NBI Sustainable Canadian Bond ..

+0.05 (+0.22%)

CAD 2.78B

ETFs Containing MHCD:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.66% 89% A- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.66% 89% A- 81% B-
Trailing 12 Months  
Capital Gain 5.48% 47% F 43% F
Dividend Return 3.48% 72% C 60% D-
Total Return 8.96% 51% F 44% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.72% 45% F 42% F
Dividend Return 3.29% 44% F 36% F
Total Return 0.57% 70% C- 29% F
Risk Return Profile  
Volatility (Standard Deviation) 6.26% 74% C 87% B+
Risk Adjusted Return 52.57% 60% D- 62% D
Market Capitalization 0.16B 71% C- 42% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.